Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).
Aptorum Group is set to choose at least three repurposed drug candidates for Covid-19 treatment, out of nearly 2,600 approved small drug molecules screened using its Smart-ACT drug discovery platform.
Aptorum Group Limited has announced the appointment of Dr. Thomas Wai-yip Lee as Head of Research and Development and Dr. Angel Siu-yan Ng as Chief Operating Officer of Aptorum, effective on April 1, 2019.